Share on StockTwits

Smith & Nephew plc (LON:SN)‘s stock had its “outperform” rating restated by equities researchers at Sanford C. Bernstein in a research report issued on Wednesday. They currently have a GBX 1,160 ($19.76) price objective on the stock. Sanford C. Bernstein’s price target suggests a potential upside of 11.11% from the company’s current price.

A number of other analysts have also recently weighed in on SN. Analysts at Numis Securities Ltd reiterated a “hold” rating on shares of Smith & Nephew plc in a research note on Tuesday. They now have a GBX 1,000 ($17.03) price target on the stock. Separately, analysts at BNP Paribas raised their price target on shares of Smith & Nephew plc from GBX 1,000 ($17.03) to GBX 1,250 ($21.29) in a research note on Wednesday, June 25th. They now have an “outperform” rating on the stock. Finally, analysts at Goldman Sachs reiterated a “neutral” rating on shares of Smith & Nephew plc in a research note on Tuesday, June 24th. They now have a GBX 1,070 ($18.23) price target on the stock. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and nine have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of GBX 959.63 ($16.35).

Shares of Smith & Nephew plc (LON:SN) opened at 1040.00 on Wednesday. Smith & Nephew plc has a 1-year low of GBX 720.00 and a 1-year high of GBX 1136.00. The stock has a 50-day moving average of GBX 1018. and a 200-day moving average of GBX 930.7. The company’s market cap is £9.287 billion.

Smith & Nephew plc is a global medical devices business operating in the markets for orthopaedic reconstruction and trauma, endoscopy (LON:SN) and advanced wound management.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.